OBX-115: A Promising TIL Therapy for Melanoma
Source: Targeted Oncology, July 2024
OBX-115 is a novel engineered tumor infiltrating lymphocyte (TIL) therapy designed to treat patients with checkpoint inhibitor-resistant metastatic melanoma. Unlike traditional TIL therapies that require toxic high-dose interleukin-2 (IL2), OBX-115 incorporates a regulated IL15 system, eliminating the need for this harmful cytokine.
Early results from a phase 1 study (NCT05470283) are encouraging. OBX-115 was well-tolerated with no severe adverse effects. Importantly, it demonstrated significant antitumor activity, leading to durable responses in half of the patients studied. This includes 2 complete remissions and 1 partial remission. The therapy also showed no sign of promoting brain metastases, a common concern with cancer treatments.
These findings suggest that OBX-115 has the potential to be a safe and effective treatment option for patients with advanced melanoma who have failed other therapies. Further studies are ongoing to confirm these promising results.